StockNews.com Upgrades MediWound (NASDAQ:MDWD) to "Sell"

MediWound (NASDAQ:MDWD - Get Free Report) was upgraded by research analysts at StockNews.com to a "sell" rating in a research note issued on Friday.

MDWD has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of MediWound in a report on Thursday, March 20th. Craig Hallum began coverage on shares of MediWound in a research note on Friday, February 28th. They set a "buy" rating and a $39.00 price target on the stock.

MediWound Price Performance

Shares of MediWound stock traded up $0.21 on Friday, reaching $16.66. 82,273 shares of the company traded hands, compared to its average volume of 90,003. The firm has a market capitalization of $179.81 million, a PE ratio of -5.74 and a beta of 0.82. The company has a 50 day moving average of $18.08 and a 200 day moving average of $17.59. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period last year, the business posted ($0.19) earnings per share. As a group, analysts anticipate that MediWound will post -2.66 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. MetLife Investment Management LLC purchased a new stake in shares of MediWound in the third quarter worth about $89,000. Investor AB purchased a new stake in MediWound in the 3rd quarter worth approximately $15,750,000. Point72 Asset Management L.P. bought a new position in MediWound in the 3rd quarter valued at $212,000. State Street Corp grew its position in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock valued at $1,197,000 after purchasing an additional 45,529 shares in the last quarter. Finally, Barclays PLC grew its position in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock valued at $202,000 after purchasing an additional 8,449 shares in the last quarter. Institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.